Initiation of first disease-modifying treatment for multiple
sclerosis patients in the Czech republic from 2013 to 2016:
Data from the national registry ReMuS

J 2019

Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS

HORAKOVA, D., P. ROCKOVA, J. JIRCIKOVA, Tomáš DOLEŽAL, M. VACHOVA et. al.

Basic information

Original name

Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS

Authors

HORAKOVA, D. (203 Czech Republic, guarantor), P. ROCKOVA (203 Czech Republic), J. JIRCIKOVA (203 Czech Republic), Tomáš DOLEŽAL (203 Czech Republic, belonging to the institution), M. VACHOVA (203 Czech Republic), P. HRADILEK (203 Czech Republic), M. VALIS (203 Czech Republic), J. SUCHA (203 Czech Republic), A. MARTINKOVA (203 Czech Republic), R. AMPAPA (203 Czech Republic), M. GRUNERMELOVA, I. STETKAROVA, Pavel ŠTOURAČ (203 Czech Republic, belonging to the institution), J. MARES (203 Czech Republic), Michal DUFEK (203 Czech Republic, belonging to the institution), E. KMETOVA (203 Czech Republic), J. ADAMKOVA (203 Czech Republic) and T. HRNCIAROVA (203 Czech Republic)

Edition

MULTIPLE SCLEROSIS AND RELATED DISORDERS, OXFORD, ELSEVIER SCI LTD, 2019, 2211-0348

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30103 Neurosciences

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.889

RIV identification code

RIV/00216224:14110/19:00111752

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.msard.2019.08.003

UT WoS

000495743000037

Keywords in English

Multiple sclerosis; Czech national registry ReMuS; Disease-modifying drugs; Quality of care; Treatment initiation

Abstract

V originále

Background: : Proper management of multiple sclerosis (MS) requires feedback from clinical practice via registries. Objective: : To introduce the Czech national multiple sclerosis registry, ReMuS, and explore the availability and use of disease-modifying drugs (DMD). Methods: : The analysis focused on patients who started their first DMD, either with first-line or second-line medication and was based on reimbursement criteria set by Czech regulators. Baseline information was used to predict relapses after DMD initiation and to compare patients that started DMD in different years. Results: : A total of 3,328 patients started DMD treatment for MS between 2013 and 2016; 3,203 on first-line and 125 on second-line medication. The proportion of patients starting on second-line drugs increased from 1.8% in 2013 to 4.7% in 2016. The occurrence of a relapse within one year of DMD initiation was significantly related to (1) the Expanded Disability Status Scale (EDSS) score immediately prior to starting DMD and (2) the number of previous relapses. Both parameters were significantly lower in patients starting in later years of the explored interval. Conclusion: : Data from the ReMuS registry highlights improvements made in the management of MS in the Czech Republic. However, a relatively low percentage of patients started treatment using second-line drugs, in contrast to trends in other countries.

Citovat

HORAKOVA, D., P. ROCKOVA, J. JIRCIKOVA, Tomáš DOLEŽAL, M. VACHOVA, P. HRADILEK, M. VALIS, J. SUCHA, A. MARTINKOVA, R. AMPAPA, M. GRUNERMELOVA, I. STETKAROVA, Pavel ŠTOURAČ, J. MARES, Michal DUFEK, E. KMETOVA, J. ADAMKOVA and T. HRNCIAROVA. Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS. MULTIPLE SCLEROSIS AND RELATED DISORDERS. OXFORD: ELSEVIER SCI LTD, 2019, vol. 35, OCT 2019, p. 196-202. ISSN 2211-0348. Available from: https://dx.doi.org/10.1016/j.msard.2019.08.003.

@article{1593236,
   author = {Horakova, D. and Rockova, P. and Jircikova, J. and Doležal, Tomáš and Vachova, M. and Hradilek, P. and Valis, M. and Sucha, J. and Martinkova, A. and Ampapa, R. and Grunermelova, M. and Stetkarova, I. and Štourač, Pavel and Mares, J. and Dufek, Michal and Kmetova, E. and Adamkova, J. and Hrnciarova, T.},
   article_location = {OXFORD},
   article_number = {OCT 2019},
   doi = {http://dx.doi.org/10.1016/j.msard.2019.08.003},
   keywords = {Multiple sclerosis; Czech national registry ReMuS; Disease-modifying drugs; Quality of care; Treatment initiation},
   language = {eng},
   issn = {2211-0348},
   journal = {MULTIPLE SCLEROSIS AND RELATED DISORDERS},
   title = {Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS},
   url = {http://dx.doi.org/10.1016/j.msard.2019.08.003},
   volume = {35},
   year = {2019}
}

TY  - JOUR
ID  - 1593236
AU  - Horakova, D. - Rockova, P. - Jircikova, J. - Doležal, Tomáš - Vachova, M. - Hradilek, P. - Valis, M. - Sucha, J. - Martinkova, A. - Ampapa, R. - Grunermelova, M. - Stetkarova, I. - Štourač, Pavel - Mares, J. - Dufek, Michal - Kmetova, E. - Adamkova, J. - Hrnciarova, T.
PY  - 2019
TI  - Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS
JF  - MULTIPLE SCLEROSIS AND RELATED DISORDERS
VL  - 35
IS  - OCT 2019
SP  - 196-202
EP  - 196-202
PB  - ELSEVIER SCI LTD
SN  - 22110348
KW  - Multiple sclerosis
KW  - Czech national registry ReMuS
KW  - Disease-modifying drugs
KW  - Quality of care
KW  - Treatment initiation
UR  - http://dx.doi.org/10.1016/j.msard.2019.08.003
L2  - http://dx.doi.org/10.1016/j.msard.2019.08.003
N2  - Background: : Proper management of multiple sclerosis (MS) requires feedback from clinical practice via registries. Objective: : To introduce the Czech national multiple sclerosis registry, ReMuS, and explore the availability and use of disease-modifying drugs (DMD). Methods: : The analysis focused on patients who started their first DMD, either with first-line or second-line medication and was based on reimbursement criteria set by Czech regulators. Baseline information was used to predict relapses after DMD initiation and to compare patients that started DMD in different years. Results: : A total of 3,328 patients started DMD treatment for MS between 2013 and 2016; 3,203 on first-line and 125 on second-line medication. The proportion of patients starting on second-line drugs increased from 1.8% in 2013 to 4.7% in 2016. The occurrence of a relapse within one year of DMD initiation was significantly related to (1) the Expanded Disability Status Scale (EDSS) score immediately prior to starting DMD and (2) the number of previous relapses. Both parameters were significantly lower in patients starting in later years of the explored interval. Conclusion: : Data from the ReMuS registry highlights improvements made in the management of MS in the Czech Republic. However, a relatively low percentage of patients started treatment using second-line drugs, in contrast to trends in other countries.
ER  -

HORAKOVA, D., P. ROCKOVA, J. JIRCIKOVA, Tomáš DOLEŽAL, M. VACHOVA, P. HRADILEK, M. VALIS, J. SUCHA, A. MARTINKOVA, R. AMPAPA, M. GRUNERMELOVA, I. STETKAROVA, Pavel ŠTOURAČ, J. MARES, Michal DUFEK, E. KMETOVA, J. ADAMKOVA and T. HRNCIAROVA. Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS. \textit{MULTIPLE SCLEROSIS AND RELATED DISORDERS}. OXFORD: ELSEVIER SCI LTD, 2019, vol.~35, OCT 2019, p.~196-202. ISSN~2211-0348. Available from: https://dx.doi.org/10.1016/j.msard.2019.08.003.

Detailed Information on Publication Record